Antigenicity and Protective Efficacy of a Leishmania Amastigote-specific Protein, Member of the Super-oxygenase Family, against Visceral Leishmaniasis

PLoS Neglected Tropical Diseases

Volumn 7, Issue 3, 2013, Pages

  Martins, Vivian T ^a   Chávez Fumagalli, Miguel A ^a   Costa, Lourena E ^a   Martins, Adriana M C C ^a   Lage, Paula S ^a   Lage, Daniela P ^a   Duarte, Mariana C ^a   Valadares, Diogo G ^a   Magalhães, Rubens D M ^a   Ribeiro, Tatiana G ^a   Nagem, Ronaldo A P ^a   DaRocha, Wanderson D ^b   Régis, Wiliam C B ^c   Soto, Manuel ^d   Coelho, Eduardo A F ^a   Fernandes, Ana Paula ^a   Tavares, Carlos A P ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF MINAS GERAIS   (Brazil)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; LEISHMANIA AMASTIGOTE SPECIFIC PROTEIN; PROTOZOAL PROTEIN; SAPONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; DOG; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOBLOTTING; IMMUNOGENICITY; MOUSE; NONHUMAN; PARASITE LOAD; SERODIAGNOSIS; T LYMPHOCYTE; VISCERAL LEISHMANIASIS;

EID: 84875972314     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002148     Document Type: Article

References (44)

1. Croft SL, Coombs GH, (2003) Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19: 502-508.
2. Minodier P, Parola P, (2010) Cutaneous leishmaniasis treatment. Travel Med Infect Dis 5: 150-158.
3. Mondal S, Bhattacharya P, Ali N, (2010) Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther 8: 919-944.
4. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, et al. (2011) Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 118: 87-96.
5. Das A, Ali N, (2012) Vaccine prospects of killed but metabolically active Leishmania against visceral leishmaniasis. Expert Rev Vaccines 11: 783-785.
6. Green SJ, Mellouk S, Hoffman SL, Meltzer MS, Nacy CA, (1990) Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol Lett 25: 15-19.
7. Blackwell JM, (1996) Genetic susceptibility to leishmanial infections: studies in mice and man. Parasitology 112: S67-S74.
8. Wilson ME, Jeronimo SM, Pearson RD, (2005) Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 38: 147-160.
9. Stäger S, Alexander J, Carter KC, Brombacher F, Kaye PM, (2003) Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect Immun 71: 4804-4807.
10. Stäger S, Smith DF, Kaye PM, (2000) Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165: 7064-7071.
11. Dondji B, Perez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D, (2005) Heterologous prime - boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 73: 5286-5289.
12. Chávez-Fumagalli MA, Costa MA, Oliveira DM, Ramírez L, Costa LE, et al. (2010) Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge. Microbes Infect 12: 967-977.
13. Agallou M, Smirlis D, Soteriadou KP, Karagouni E, (2012) Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis. Vaccine 30: 5086-5093.
14. Wenzel UA, Bank E, Florian C, Forster S, Zimara N, et al. (2012) Leishmania major parasite stage-dependent host cell invasion and immune evasion. Faseb J 26: 29-39.
15. Fernandes AP, Coelho EAF, Machado-Coelho GLL, Grimaldi JrG, Gazzinelli RT, (2012) Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives. Curr Opin Microbiol 15: 1-10.
16. Coelho VT, Oliveira JS, Valadares DG, Chávez-Fumagalli MA, Duarte MC, et al. (2012) Identification of proteins in promastigote and amastigote-like Leishmania using an immunoproteomic approach. PLoS Negl Trop Dis 6: e1430.
17. Coelho EA, Tavares CAP, Carvalho FAA, Chaves KF, Teixeira KN, et al. (2003) Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 71: 3988-3994.
18. Vieira LQ, Goldschmidt M, Nashleanas M, Pfeffer K, Mak T, et al. (1996) Mice lacking the TNF receptor p55 fail to resolve lesions caused by infection with Leishmania major, but control parasite replication. J Immunol 157: 827-835.
19. Lima MM, Sarquis O, de Oliveira TG, Gomes TF, Coutinho C, et al. (2012) Investigation of Chagas disease in four periurban areas in northeastern Brazil: epidemiologic survey in man, vectors, non-human hosts and reservoirs. Trans R Soc Trop Med Hyg 106: 143-149.
20. Roque AL, Xavier SC, Gerhardt M, Silva MF, Lima VS, et al. (2012) Trypanosoma cruzi among wild and domestic mammals in different areas of the Abaetetuba municipality (Pará State, Brazil), an endemic Chagas disease transmission area. Vet Parasitol 193: 71-7doi:pii:S0304-4017(12)00613-9.10.1016/j.vetpar.2012.11.028.
21. Coelho EAF, Ramirez L, Costa MAF, Coelho VTS, Martins VT, et al. (2009) Specific serodiagnosis of canine visceral leishmaniasis using Leishmania species ribosomal protein extracts. Clin Vaccine Immunol 16: 1774-1780.
22. Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Costa MMS, et al. (2007) Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Microbes Infect 9: 1070-1077.
23. Fernandes AP, Costa MM, Coelho EA, Michalick MS, de Freitas E, et al. (2008) Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 26: 5888-5895.
24. Resende DM, Caetano BC, Dutra MS, Penido ML, Abrantes CF, et al. (2008) Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8 T cells. Vaccine 26: 4585-4593.
25. Bhowmick S, Ravindran R, Ali N, (2008) gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun 76: 1003-1015.
26. Rachamim N, Jaffe CL, (1993) Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J Immunol 150: 2322-2331.
27. Awasthi A, Mathur RK, Saha B, (2004) Immune response to Leishmania infection. Indian J Med Res 119: 238-258.
28. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP, (2001) IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31: 2848-2856.
29. Murray HW, Lu CM, Mauze S, Freeman S, Moreira AL, et al. (2002) Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 70: 6284-6293.
30. Pereira BA, Alves CR, (2008) Immunological characteristics of experimental murine infection with Leishmania (Leishmania) amazonensis. Vet Parasitol 158: 239-255.
31. Garg R, Dube A, (2006) Animal models for vaccine studies for visceral leishmaniasis. Indian J Med Res 12: 439-454.
32. Ghosh A, Zhang WW, Matlashewski G, (2001) Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infection. Vaccine 20: 59-66.
33. Iborra S, Parody N, Abanades DR, Bonay P, Prates D, et al. (2008) Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect 10: 1133-1141.
34. Dumas C, Muyombwe A, Roy G, Matte C, Ouellette M, et al. (2003) Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect Immun 71: 6499-6509.
35. Murray HW, Cervia JS, Hariprashad J, Taylor AP, Stoeckle MY, et al. (1995) Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J Clin Invest 95: 1183-1192.
36. Follador I, Araujo C, Orge G, Cheng LH, de Carvalho LP, et al. (2002) Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor. Vaccine 20: 1365-1368.
37. Badaró R, Lobo I, Nakatani M, Muinos A, Netto EM, et al. (2001) Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report. Braz J Infect Dis 5: 223-232.
38. Gomes R, Teixeira C, Teixeira MJ, Oliveira F, Menezes MJ, et al. (2008) Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci U S A 105: 7845-7850.
39. Afrin F, Anam K, Ali N, (2000) Induction of partial protection against Leishmania donovani by promastigoyes antigens in negatively charged liposomes. J Parasitol 89: 730-735.
40. Carrión J, Nieto A, Iborra S, Iniesta V, Soto M, et al. (2006) Immunohistological features of visceral leishmaniasis in BALB/c mice. Parasite Immunol 28: 173-183.
41. Oliveira DM, Valadares DG, Duarte MC, Costa LE, Martins VT, et al. (2012) Evaluation of parasitological and immunological parameters of Leishmania chagasi infection in BALB/c mice using different doses and routes of inoculation of parasites. Parasitol Res 110: 1277-1285.
42. Requena JM, Iborra S, Carrion J, Alonso C, Soto M, (2004) Recent advances in vaccines for leishmaniasis. Expert Opin Biol Ther 4: 1505-1517.
43. Ahmed S, Colmenares M, Soong L, Goldsmith-Pestana K, Munstermann L, et al. (2003) Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect Immun 71: 401-410.
44. Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, et al. (2009) Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28: 53-62.